Related Experiment Video

Updated: Jun 4, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Epigenetics of thyroid cancer and novel therapeutic targets

Diego Russo1, Giuseppe Damante, Efisio Puxeddu

  • 1Dipartimento di Scienze Farmacobiologiche, Università di Catanzaro, 88100 Catanzaro, Italy. d.russo@unicz.it

Journal of Molecular Endocrinology
|February 18, 2011
PubMed

Insights

Epigenetic changes are crucial in thyroid cancer development and progression. Investigating these alterations offers new therapeutic strategies targeting epigenetic modifications for improved patient outcomes.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Epigenetic alterations, including DNA methylation and chromatin remodeling, are increasingly recognized in thyroid tumorigenesis.
  • These changes affect tumor cell differentiation, proliferation, and gene expression, impacting radioiodine uptake and treatment efficacy.

Purpose of the Study:

  • To review the mechanisms of epigenetic regulation in gene expression.
  • To summarize principal epigenetic alterations in thyroid cancer cells.
  • To explore epigenetic strategies and therapeutic agents for thyroid cancer treatment.

Main Methods:

  • Overview of epigenetic regulatory mechanisms.
  • Review of current investigation methods for epigenetic changes.
  • Analysis of preclinical and clinical data on epigenetic therapies.

Main Results:

  • Epigenetic silencing of thyroid-specific genes is observed in thyroid tumors, reducing radioiodine concentration.
  • Alterations in tumor-promoting and tumor-suppressor genes dysregulate thyrocyte growth, apoptosis, motility, and invasiveness.
  • Demethylating agents and histone deacetylase inhibitors show potential in preclinical and clinical studies.

Conclusions:

  • Epigenetic modifications are key drivers in thyroid cancer.
  • Understanding these changes is vital for developing targeted therapies.
  • Epigenetic-based treatments, such as demethylating agents and HDAC inhibitors, represent a promising therapeutic avenue for thyroid cancer.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...